Collagen Derived Serum Markers in Carcinoma of the Prostate
- 1 September 1995
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Urology and Nephrology
- Vol. 29 (3) , 317-321
- https://doi.org/10.3109/00365599509180582
Abstract
Three new collagen markers deriving from the collagenous matrix, e.g. carboxyterminal propeptide of type I procollagen (PICP), carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen (ICTP), and aminoterminal propeptide of type III procollagen (PIIINP) were used for the diagnose of prostatic bone metastases. Blood samples were obtained prior to biopsy or TURP. Serum PICP, PIIINP and ICTP were measured with commercial available RIAs and PSA by IRMA. Serum PSA was increased in patients with local prostatic cancer compared with patients with hyperplasia (p < 0.05). The level of PIIINP, ICTP, and PICP did not differ between these two groups. In patients with metastatic prostatic cancer all five markers were increased compared to the level measured in patients with localized cancer (p < 0.0001). All variables showed a significant positive relationship with alkaline phosphatase. The sensitivity ranged from 0.53 to 0.62 and specificity from 0.91 to 0.95. The sensitivity for alkaline phosphatase and PSA was 0.69 and 0.66 and specificity 0.91 and 0.68, respectively.Keywords
This publication has 16 references indexed in Scilit:
- Tumor markers in prostate cancerCancer, 1992
- Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?The Prostate, 1992
- Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the ProstateJournal of Urology, 1991
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Some Limitations of the Radioisotope Bone Scan in Patients With Metastatic Prostatic CancerCancer, 1990
- Multivariate Analysis of Prognostic Factors in Patients with Advanced Prostatic Cancer: Results from 2 European Organization for Research on Treatment of Cancer TrialsJournal of Urology, 1989
- Osteocalcin: a potential marker of metastatic bone disease and response to treatmentEuropean Journal of Cancer and Clinical Oncology, 1988
- Treatment of Advanced Prostatic CancerUrologic Clinics of North America, 1987
- Do Bone Scans Predict Prognosis in Prostatic Cancer? A Report of the EORTC Protocol 30762British Journal of Urology, 1984
- Comparison of Enzyme, Clinical, Radiographic, and Radionuclide Methods of Detecting Bone Metastases from Carcinoma of the ProstateRadiology, 1976